ARS Pharmaceuticals (SPRY) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.63

Estimate

-$0.49

Surprise

-27.7%

Revenue (period 2026-06-30)

$33.7M

Score today

5.8/10

Revenue source: xbrl.

ARS Pharmaceuticals (SPRY) reported a wider loss than forecast — diluted EPS of -$0.63 against the -$0.49 estimate (a 27.7% shortfall).

• Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s — benzinga, 2026-08-14
• Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket — benzinga, 2026-08-14
• ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript — benzinga, 2026-08-13

TrendMatrix currently rates SPRY Sell at 5.8/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -27.7% surprise compares with a -8.8% four-quarter average. Next scheduled report: 2026-11-10.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$5.50

Price target

$6.45

Stop

$5.12

Upside to target

+17.3%

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$547.5M

P/E (fwd)

-6.2

52-week range

$4.91–$14.00

Off 52-week high

60.7%

RSI (14)

51

Volume vs avg

0.60×

Score today

5.8/10